StreetAlpha.app
Home › Stocks › ZURA

Zura Bio Ltd (ZURA)

Healthcare
$0.93
▼ −2.30%
LAST CLOSE · NOV 20

Zura Bio develops antibody medicines for autoimmune and inflammatory diseases, and has no approved products yet. It last closed at $0.93 on Nov 20, down 2.30% on the day. The next earnings report for ZURA is expected around Wed, Feb 24, 2027, after the close. For the quarter ended Sep 2026, ZURA reported EPS of -$0.20. Over its last 8 reports the stock moved an average of 7.8% the session after earnings. Over the last 12 months ZURA insiders bought $12.5M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is ZURA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ZURA.

Key Stats

Last 12 months
Results
Net income
−$93.5M
EPS (diluted)
−$1.11
Free cash flow
−$64.9M
Valuation
Market cap
$89.6M
96.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$187.7M
At Sep 30
Shares outstanding
96.3M
At Oct 27
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: −$25.7M−$25.7MFY2022FY2023: −$60.4M−$60.4MFY2023FY2024: −$52.4M−$52.4MFY2024FY2025: −$68.7M−$68.7MFY2025

From ZURA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 27). Last 12 months adds up the four latest quarters.

Next report
Feb 24
Estimated date · After the close
Reported EPS
-$0.20
Quarter ended Sep 2026
Year ago EPS
-$0.21
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.08Dec '24Mar 2025: -$0.19Mar '25Jun 2025: -$0.17Jun '25Sep 2025: -$0.21Sep '25Dec 2025: -$0.49Dec '25Mar 2026: -$0.22Mar '26Jun 2026: -$0.21Jun '26Sep 2026: -$0.20Sep '26Latest -$0.20
Revenue by quarter
Not enough quarters on file yet.
How ZURA moved after its last 8 reports
Average move the session after a report ±7.8%
Oct 27, 2026Time not announced+19.9%
Aug 11, 2026Time not announced−1.2%
May 7, 2026Time not announced−7.2%
Feb 25, 2026After the close−3.3%
Nov 13, 2025Time not announced−9.7%
Aug 14, 2025Time not announced+8.2%
May 8, 2025Time not announced+2.4%
Mar 25, 2025Time not announced+10.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ZURAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ZURA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ZURA

Technical Analysis

ZURA · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 176% below its 20 day and 280% below its 50 day average. It is 432% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the 52 week low at $0.92, and the nearest resistance the Pivot at $0.95.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 42.2%/day
Key levels
$7.4452 week high+700.0%
$4.95200 day average+432.3%
$4.56100 day average+390.3%
$3.85Swing high (Jun 15)+314.0%
$3.5450 day average+280.6%
$2.5720 day average+176.3%
$0.98Pivot R1+5.4%
$0.95Pivot+2.2%
$0.93Last close
$0.9252 week low−1.1%
$0.90Pivot S1−3.2%
Indicators
RSI (14)24.24Oversold below 30Oversold
MACD-0.87Below its signal lineBearish
Stochastic0.7Near the bottom of its rangeOversold
ADX (14)30.4Trending down
Williams %R-99.7Oversold below −80, overbought above −20Oversold
CCI (20)-76.2Oversold below −100, overbought above 100Neutral
Rate of change−77.3%Change over 10 sessionsBearish
ATR (14)$0.39Typical daily range, 42.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ZURA

What happened before

See how ZURA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ZURA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ZURA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ZURAHow many large options trades hit ZURA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ZURA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲67 buying vs 41 selling
  • ▼Held by funds -3.7 pts
  • ▲Funds holding +27
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding12295+28.4%
In funds' top 10110.0%
Held by funds72.0%75.7%−3.7 pts
New / increased33 / 3426 / 32+15.5%
Reduced / sold out35 / 619 / 24−4.7%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ZURA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ZURA Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$12.5M1 buy · 1 insider
Sold$00 sales · 0 insiders
2026-02 bought $12.5MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Feb 26Access Industries Holdings LLC10% ownerBuy2,000,000$6.25$12.5M
Nov 25, 2024Parvinder ThiaraDirectorSale1,001,633$2.73$2.7M
Every insider buy and sale for ZURA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ZURA insider trades →

From SEC Form 4 filings by ZURA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZURA is in one of them and how their past ZURA trades turned out.

ZURA in the AI portfolios
Loading…

ZURA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ZURA in an article yet. Here's the latest on the wider market.

ZURA in the news

About Zura Bio

Zura Bio is a biotechnology company based in La Jolla, California, that develops antibody medicines for people with autoimmune and inflammatory diseases. Its tibulizumab candidate is designed to block two immune signals, IL-17A and BAFF, within a single molecule. The company also has crebankitug and torudokimab, which target other immune pathways. Tibulizumab is in two Phase 2 trials, in hidradenitis suppurativa and diffuse cutaneous systemic sclerosis, and no Zura Bio medicine is yet approved for sale.

Headquarters
La Jolla, CA